Rhabdomyolyse fatale sous cerivastatine.

Scheen, André

No full text

Article (Scientific journals)

Rhabdomyolyse fatale sous cerivastatine.

Scheen, André

2001 • In Revue Médicale de Liège, 56 (8), p. 592-4

Peer reviewed

Permalink
https://hdl.handle.net/2268/12128

PubMed
11584446

Files (0)Send to Details Statistics Bibliography Similar publications

Files

Full Text

No document available.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects; Pyridines/adverse effects; Rhabdomyolysis/chemically induced

Abstract :

[en] Cerivastatin was recently withdrawn from the market after the report of more than 30 deaths in the United-States among patients receiving a combination of cerivastatin and gemfibrozil, a fibrate which is not anymore on the Belgian market. The cause of death was attributed to severe rhabdomyolysis. Cases were also reported among patients treated by cerivastatin only. Recommendations for better use of lipid-lowering drugs are given in order to optimize the benefit/risk ratio of such treatment.

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

Rhabdomyolyse fatale sous cerivastatine.

Alternative titles :

[fr] Fatal rhabdomyolysis caused by cerivastatin

Publication date :

2001

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Hopital de Baviere, Liège, Belgium

Volume :

Issue :

Pages :

592-4

Peer reviewed :

Peer reviewed

Available on ORBi :

since 05 May 2009

Statistics

Number of views

97 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Scheen A.J. (1999) Le risque cardio-vasculaire lié à l'hyper cholestéolémie: D'un continuum à la notion de normalité, de seuil d'intervention et d'objectif thérapeutique. Rev Med Liège 54:17-21.
Ducobu J., Scheen A.J. (2000) Les recommandations du Belgian Lipid Club pour le diagnostic et le traitement des hyperlipidémies: Résumé pour le praticien. Rev Med Liège 55:360-366.
Scheen A.J. (1999) Traitement de l'hyperlipidémie combinée: Fibrate ou/et statine?. Rev Med Liège 54:583-587.
Scheen A.J. (1992) Le traitement des hyperlipidémies. Rev Med Liège 47:169-184.
Smit J.W.A., Jansen G.H., De Bruin T.W.A., Erkelens D.W. (1995) Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am J Cardiol 76.
Da Col P., Cattin L. (1993) Tolerability and efficacy of combination therapy with simvastatin plus gemfibrozil in type IIb refractory familial combined hyperlipidemia. Curr Ther Res 43:473-483.
Hutchesson A., Jones A. (1994) Dual bezafibrate-simvastatin therapy for combined hyperlipidemia. J Clin Pharm Ther 19:387-389.
Athyros V.G., Papageorgiou A.A., Hatzikonstandinou H.A. (1997) Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 80:608-613.
Ellen R.L.B., Mcpherson R. (1998) Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 81(SUPPL.).
Tikkanen M.J., Laakso M., Ilmonen M. (1998) Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM: A multicenter comparison study. Diabetes Care 21:477-481.
Shepherd J. (1995) Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety. Eur Heart J 16:5-13.
Scheen A.J. (2000) Le médicament du mois. La cérivastatine (Lipobay®, Cholstat®). Rev Med Liège 55:117-120.
McClellan K.J., Wiseman L.R., McTavish D. (1998) Cerivastatin. Drugs 55:415-420.
Frick M.H., Haapa K., Heinonen O.P. (1987) Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317:1237-1245.
Rubins H.B., Robins S.J., Collins D. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410-418.
Scheen A.J. (1999) Etude clinique du mois. Intérêt d'augmenter un taux de cholesterol HDL bas en prévention secondaire de la coronaropathie: Résultats de l'étude VA-HIT. Rev Med Liège 54:773-775.
Farmer J.A. (1998) Aggressive lipid therapy in the statin era. Prog Cardiovasc Dis 41:71-94.
Gould A.L., Rossouw J.E., Santanello N.C. (1998) Cholesterol reduction yields clinical benefit: Impact of statin trials. Circulation 97:946-952.